Thursday, May 21, 2009, 9:30am
O’Malley: Maryland’s biotech strategy to get funding boost
Baltimore Business Journal - by Julekha Dash Staff
Maryland plans to increase funding for the Maryland Venture Fund and a biotechnology tax credit to boost the state’s $29 billion life sciences industry.
Gov. Martin O’Malley unveiled a more detailed version of the state’s 10-year, $1.3 billion strategy Wednesday afternoon at the BIO 2009 Convention in Atlanta. The convention attracted more than 400 attendees from Maryland, including a delegation of 30 Maryland bioscience companies. State officials and biotech executives made the trip with the hopes of landing new biotech companies for Baltimore and getting investors that have been scarce since the downturn.
Offering access to capital is a key piece of the state’s Bio 2020 plan.
The roadmap includes increasing the Maryland Venture Fund from $2 million to $24 million by 2020 and raising the biotech tax credit from $6 million to $24 million by 2020.
On Monday, O’Malley said the state will open two biotechnology centers in Rockville and Baltimore in the next 30 days. Other features of the Bio 2020 plan include:
• Establishing a bioscience commercialization institute that can help speed up drug discoveries;
• Creating a venture capital trust with $10 million in seed capital;
• Branding Maryland as a leader in the biotech industry;
• Providing loans of up to $5 million to bioscience companies that are in the later stages of product development;
• Increasing funding for technology transfer initiatives at research universities.
The proposals were made at the recommendation of a 15-member life sciences advisory board, which solicited input from more than 100 industry experts to devise the plan.
Thursday, May 21, 2009
Thursday, May 21, 2009, 9:30am
at 3:41 PM
Very moving story about a mother's fight to get the right to use Iplex in the care of her son suffering from Lou Gehrig's disease.
May 17, 2009
Months to Live
Fighting for a Last Chance at Life
By AMY HARMON
VIRGINIA BEACH — As Lou Gehrig’s disease sapped Joshua Thompson of his ability to move and speak last fall, he consistently summoned one question from within the prison of his own body. “Iplex,” he asked, in a whisper that pierced his mother’s heart. “When?”
Iplex had never been tested in people with amyotrophic lateral sclerosis, the formal name for the fatal disease that had struck Joshua, 34, in late 2006. Developed for a different condition and banished from the market by a patent dispute, it was not for sale to the public anywhere in the world.
But Kathy Thompson had vowed to get it for her son. On the Internet, she had found enthusiastic reviews from A.L.S. patients who had finagled a prescription for Iplex when it was available, along with speculation by leading researchers as to why it might slow the progressive paralysis that marks the disease. And for months, as she begged and bullied biotechnology companies, members of Congress, Italian doctors and federal drug regulators, she answered Joshua the same way:
“Soon,” she said. “Soon.”
At a time when terminally ill patients have more access to medical research than ever before, and perhaps a deeper conviction in its ability to cure them, many are campaigning for the chance to be treated with drugs whose safety and effectiveness is not yet known.
But even as advances in areas like stem cells and genetics generate greater hope for experimental therapies, there is little consensus on how and when to provide them to dying patients whose lives could be prolonged, or shortened, by trying them.
Insurance companies typically do not pay for drugs that are part of a not-quite-finished scientific process. But even affluent families like the Thompsons find themselves pleading simply for the right to buy a drug, with institutions and individuals that often seem to them to have no logic — and sometimes no heart.
Doctors worry about instilling false hope and doing unnecessary harm. Companies fear damaging a drug’s chance of winning approval from the Food and Drug Administration if a patient suffers a bad reaction. The F.D.A. itself does not want patients to bypass clinical trials, which require that some participants receive a placebo to determine reliably whether a drug works.
Some patient advocates are lobbying for laws and policies that would sanction what has become known as the “compassionate use” of experimental drugs by seriously ill patients who have run out of other options. But for now, each appeal to the guardians of untested drugs is an improvisation, in which success relies on connections, determination, mercy and luck, and the hope of prevailing can sometimes eclipse the hope held out for the drug itself.
The Search for a Treatment
Kathy discovered Iplex deep in the pages of her first Google search for “A.L.S. and treatment” late one night in spring 2007, shortly after Joshua’s diagnosis.
In the daylight, she still had trouble believing that her athletic, magnetic son had the devastating disease with an unknown cause, named for the 1930s New York Yankees star whose career was cut short by it. When Joshua’s racquetball racket flew out of his hand because he could not grip it, his mother’s diagnosis was tennis elbow. When the first neurologist mentioned A.L.S., she scheduled more tests, rooting for Lyme’s disease, multiple sclerosis or even cancer.
But an A.L.S. specialist at Johns Hopkins University, Dr. Jeffrey D. Rothstein, had confirmed it. Like the 5,600 other people given the diagnosis each year in the United States, Dr. Rothstein said, Joshua would almost certainly die of the disease in two to five years.
The doctor prescribed the only drug approved for A.L.S., Rilutek, which typically prolongs life by a few months. Joshua, he said, would be eligible to participate in a clinical trial for another drug, Arimoclomol, that would start as soon as the F.D.A. gave the go-ahead. There was nothing else.
Except, maybe, Iplex.
To read the rest of the story, please visit the New York Times.
at 2:40 PM
Wednesday, May 20, 2009
From Steroid Nation posted by GRG51
Interesting concept: use of nanotechnology to monitor doping, even those compounds difficult to assay.
A Virginia-based biotechnology company, Ceres uses its patented Nanotrap™ -- a spherical, carbon-based nanoparticle designed to collect, concentrate, isolate and preserve the smallest and scarcest of molecules found in body fluids -- to pursue a range of applications in the diagnosis and treatment of diseases, as well as uses in sports doping screening, homeland security and environmental remediation.
Ceres and the U.S. Anti-Doping Agency have partnered to study the potential for a viable urine-based test for the detection of human growth hormone (HGH). Laboratory findings recently published in NanoLetters and Nano Research strongly suggest that development of this screening tool is highly probable, a move that would revolutionize the way college and professional sports organizations monitor potential drug use by athletes.
The Nanotrap technology also is being reviewed by SAIC-Frederick Inc., a wholly owned subsidiary of Science Applications International Corp., to determine the feasibility of developing diagnostic tools that detect cancer at the earliest possible stage when treatment is most effective.
Lab testing for a peptide (protein) hormone like HGH is always vexing. Whereas the anabolic steroids either show a long half-life, or slowly seep out of muscle, HGH exits the body relatively quickly. A sensitive way of trapping the molecule would be a boon for dope testing.
at 4:14 PM
EMILY C. DOOLEY TIMES-DISPATCH STAFF WRITERPublished: May 20, 2009
Randall "Randy" Pak stood in a long line yesterday waiting for those precious moments when he could sell himself.
Out of work since February, Pak and more than 500 other former Qimonda employees gathered at a career fair at Virginia Commonwealth University yesterday to network and talk with prospective employers about their job offerings.
"I'm looking at all opportunities right now," said Pak, who moved here from Texas two years ago to work at the now-closed memory-chip plant in eastern Henrico County.
"I think the semiconductor industry in the U.S. is really dying," Pak said. "You go through a roller coaster ride emotionally, but you just have to be optimistic."
His goal: getting some face time with the Naval Surface Warfare Center, which recently has been hiring a number of former Qimonda employees.
The lines were long to speak with one of the 18 employers attending the fair. The lines to see representatives from the Naval Surface Warfare Center ran nearly out a door.
"It was very well-attended," said Nan Stewart, district manager for Virginia for the staffing firm Kelly Scientific Resources. "The caliber of candidate was very professional among all of the levels."
Seminars on a variety of subjects were offered, including on managing finances while in career transition, crafting a résumé and applying for federal jobs.
The five-hour fair, held at VCU's School of Business and School of Engineering, was open only to former Qimonda employees.
"What I'm really after is to find someone in the logistics industry who will sit down and talk to me," said Kristian Cauffman, an engineer with a degree in geology, as he sat in the school's atrium named after Qimonda.
"I want to get away from manufacturing," he said.
The event was sponsored by VCU, the Greater Richmond Partnership and the Virginia Council on Advanced Technology Skills.
The semiconductor company had a close relationship with VCU's engineering school. The company has an endowed chair and professorship there and had been the single largest employer of engineering school graduates.
Qimonda has "done a lot for VCU," said Mike Eisenman, director of the career center for the business and engineering schools. "It's done a lot for central Virginia. We thought it was the right thing to do."
In addition to the 18 employers, 10 others that work with entrepreneurs or offer educational training attended the fair.
"There's going to be a lot of competition," said Melba Rainey-Sayed, who left Qimonda in March after nine years there. "It's like 500 people for one job. A lot of us are thinking it's time to go back to school."
Qimonda idled its two production lines at its plant in eastern Henrico this year, putting about 2,500 people out of work. The company filed for bankruptcy in February.
"To see the birth of a company and then to see it go away . . . it was important to me to help put something together," said Don Owen, the former human resources director at the Sandston plant who helped organize the fair.
"We committed to the employees that we would do something for them, and this is kind of the fulfillment of that promise."
at 1:53 PM
Monday, May 18, 2009
Virginia ranks in second tier.
Link to the Virginia Data: http://www.bio.org/local/battelle2009/VA_bio_09.pdf
States across America are failing to prepare students for pursuing biosciences in higher education—a key pipeline for developing the bioscience workforce of the future. A new report funded and researched by BIO, Battelle, and the Biotechnology Institute provides the first ever comprehensive study of middle and high school bioscience education in the 50 states, Puerto Rico, and the District of Columbia. The report also finds a wide disparity across measures of student achievement in overall science and biosciences, an uneven record across states in incorporating the biosciences in state science standards, supporting focused bioscience education programs and higher level bioscience courses, and ensuring science and bioscience teachers are well qualified.
The findings, which came to light at BIO’s annual convention, indicate a clear need for improved science education that incorporates the biosciences at the middle and high school levels if the United States bioscience industry sector is to remain globally competitive.
“The biosciences are a dynamic economic driver with a sizable footprint in nearly every state,” explains James Greenwood, President of BIO and member of the Board of the Biotechnology Institute. “The bioscience industry is a knowledge-based sector dependent upon the skills of its workers. Bioscience workers are needed to conduct research, translate innovation into product development and improved health care techniques, and ultimately to manufacture biomedical and other bioscience-related products. The prospect of the United States losing its competitive edge in student achievement and the subsequent skills of our future workforce is a matter of significant concern.”
This is not to say that bioscience education is non-existent in the United States because there are many examples of programs that work. However, the report does say that these programs should be replicated across the country and that states need to commit resources to them.
“The biosciences are the great adventure of our time, and states that aspire to play a part, either as supporters or leaders, must nurture their life science education programs," says Paul A. Hanle, president of the Biotechnology Institute. "This report rates the states' performance in life science education according to certain indicators of achievement. It also identifies best practices and programs throughout the nation. Both will be vital tools to help states wanting to strengthen their life-science education efforts."
This review of state activities in bioscience education suggests a number of actions that should be taken. For example, individual states:
Should incorporate biotechnology as they revise their science standards and should involve research scientists with expertise in the biosciences in their development.
Must commit to improving student achievement in biology and the life sciences and ensuring that their high school graduates are ready to pursue college-level bioscience courses.
Should improve the collection and dissemination of data, tracking student participation and performance in the biosciences and the broader sciences and if they do not participate in the National Assessment of Educational Progress (NAEP) science exam should be encouraged to do so.
Should take a more systematic approach to teacher professional development, experiential learning, and career awareness.
“The study recognizes the important link that high schools and middle schools have as the primary feeders to post-secondary institutions and in shaping career preparation,” explains Mitch Horowitz, Vice President and Managing Director of the Battelle Technology Partnership Practice. “The vast majority of bioscience jobs require some level of post-secondary education to ensure quality control and good manufacturing practices, conduct clinical research, design and engineer new products, or conduct research and development.”
The report provides the following evidence that states are not measuring up:
On average, only 28% of the high school students taking the ACT , which is a national standardized test for college admission, reached a score indicating college readiness for biology and no state reached even 50%.
Only 52% of 12th graders are at or above a basic level of achievement in the sciences, and for 8th graders only 57% are at a basic level of achievement.
Average scores for 12th graders in the sciences have actually declined from 1996 to 2005 and shown no improvement for 8th graders both overall and on the life science component.
A significant gap exists in science achievement for low-income middle-school students, although the gap is slowly narrowing.
Some states fared much better than others with respect to student achievement in the biosciences. While it is difficult to give a single grade across states because of the limited quality and comparability of the student achievement data, the patterns of student performance suggest the states fall into several broad categories.
Leaders of the Pack: Connecticut, Massachusetts, Minnesota, New Hampshire, New Jersey, Ohio, Vermont, Wisconsin
Second Tier: Colorado, Delaware, Illinois, Maryland, Missouri, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Virginia, Washington
Middling Performance: Alabama, Arizona, California, Hawaii, Indiana, Kentucky, Maine, Michigan, Montana, South Carolina, Wyoming
Lagging Performance: Arkansas, Florida, Georgia, Louisiana, Mississippi, Nevada, New Mexico, Oklahoma, Texas, West Virginia
Not Rated: States that do not participate in the NAEP science assessment were not rated.
The report also finds an uneven record across states in incorporating the biosciences in state science standards, supporting focused bioscience education programs and advanced bioscience courses, and ensuring well-qualified science and bioscience teachers.
Only thirty-one states reported that their science standards explicitly mention or define standards or applied laboratory or other instruction tools specifically for biotechnology or the biosciences.
At least half the states have at least one school with a bioscience focus, and all of the states have schools with a focus on broader STEM education. But states do not seem to be succeeding in encouraging high school students to take upper-level science courses. Although data on this subject are very limited, the share of students taking the AP biology exam averages 4.6% of high school graduates.
The report also notes that nearly one in eight U.S. high-school biology teachers was not certified to teach biology. The average share of biology teachers who are certified in a given state ranged from 50% to 100% in data collected by the Council of Chief State School Officers (CCSSO), although 88% of biology teachers are certified nationally on average.
The study and individual state profiles are available at: http://bio.org/battelle2009
at 5:22 PM
Friday, May 15, 2009
JOHN REID BLACKWELL TIMES-DISPATCH STAFF WRITER
Published: May 15, 2009
At a time when many small biotechnology firms are struggling to stay afloat, Richmond-based Insmed Inc. is in the enviable position of being a newly cash-rich company.
Thanks to the sale of some of its biotech drug candidates in March, the biopharmaceutical company has received a cash infusion of $125 million. That's a huge turnaround from the $2.4 million in cash the company had on hand in late December, when it was burning through about $1.2 million per month.
Insmed executives say the deal, which came after two years of work and struggles for the company, gives it a war chest to hunt for new growth opportunities, possibly by acquiring drug candidates from other biotech companies that are facing financial distress in the economic downturn.
"It's a tribute to the tenaciousness with which we've run our business over the years," said Geoffrey Allan, the company's president and chief executive officer. "Two years ago, we could have folded the tent. We didn't do that."
The money also gives Insmed a cash buffer while it continues to test one of its key drugs, Iplex, for treatment of myotonic muscular dystrophy, a genetic, muscle-wasting disease that affects about 30,000 Americans.
The timing of the deal also was important, coming just as the financial crisis has made it more difficult for biotechnology firms to raise money. About 30 percent of publicly traded biotech companies have less than six months' worth of cash on hand, while 45 percent have less than one year, according to a recent report by the Biotechnology Industry Organization, a national trade group.
"I would definitely say that Insmed is in a unique position of having significant resources on hand," said Mark Herzog, executive director of the Virginia Biotechnology Association.
"The vast majority of companies I speak to are really struggling with only having enough cash on hand to last three to six months," Herzog said. "Insmed is very well-placed to be able to continue their research and development efforts."
The deal is the latest in a series of twists and turns for Insmed, which was founded in Charlottesville in 1988 to develop diabetes drugs.
In 1995, the company became one of the first tenants of the Virginia BioTechnology Research Park in downtown Richmond. It has since moved its corporate office to Stony Point Parkway in South Richmond.
The company has taken its share of lumps in recent years, most notably in 2007, when Insmed settled a patent-infringement lawsuit filed by a competitor, which forced it to remove Iplex from the market for treatment of a rare growth disorder in children.
The settlement allowed Insmed to continue developing and marketing Iplex for other illnesses such as muscular dystrophy and Lou Gehrig's disease, but the lawsuit "had a fairly devastating effect on our business," Allan said.
In the past couple of years, the company suffered from cash-flow issues and fought to keep its shares listed on the Nasdaq stock exchange.
Setbacks come with the territory in biotech, where the outcome of product research is uncertain and financial backing is often difficult to obtain.
"I think we are pretty battle-hardened here in terms of what we have gone through," said Kevin Tully, the company's executive vice president and chief financial officer. "You are always in the situation where you are having to finish a clinical trial, manufacture a drug, and look for cash to support it. You are constantly having to adjust. As a small company, we have been able to do that. We don't have a lot of bureaucracy."
After the lawsuit settlement, Allan said, "we essentially circled the wagons and figured out what we were good at, and how to deploy the resources we had available to survive that particular blow."
Insmed's strategic solution in 2007 was to move into follow-on biologics, an area of research in developing and making generic versions of drugs produced through biological processes. The company was successful at developing several experimental versions of drugs used in therapies for cancer patients.
The strategy paid off in February when pharmaceutical company Merck & Co Inc. agreed to buy Insmed's follow-on biologics platform for $130 million. Insmed said it will have about $125 million from the deal after fees and taxes.
On Wednesday, Insmed reported a first-quarter profit of $117.8 million, compared with a loss of $4.9 million in the same period of 2008. The turnaround was largely because of the sale of its follow-on biologics business to Merck.
The deal also makes Insmed a much leaner company, with just 20 employees at its Richmond office. Its Boulder, Colo., facility, which employs 70 people, was sold as part of the Merck deal.
The company's next step is to complete testing on its Iplex drug for muscular dystrophy, which has no other drug treatment.
"We are, in many ways, pioneering development in that area," said Glen L. Kelley, the company's vice president for regulatory affairs. Though the outcome is still uncertain, "it is a great place for a company like Insmed to spend time developing drugs, because it is a niche opportunity."
Insmed executives said they are also going to carefully evaluate other opportunities such as acquisitions of potential drugs that are in the late stage of development that would help the company become profitable for the long term.
"Can we repeat the exercise and in two years have a very positive outcome?" Allan said. "I can't guarantee it, but we will all work towards it."
at 12:48 PM
Thursday, May 14, 2009
WhatCanBiotechDoForYou Question of the Day on May 13
I am a Chemical Engineer with 30+ yrs. experience in a variety of materials processing industries. Now I’m preparing to go to school to gain stronger technical background for a position in biotech. Can you refer me to any contacts for advice on specific school programs that would be most useful?May 13th, 2009
Hi Terry. Given the state of the economy, it probably shouldn’t be too surprising that our sister site http://www.iambiotech.org/ receives a lot of similar requests every week. It turns out that a good number of folks are now looking to the biotech industry when exploring their career options.
The Virginia Biotechnology Association for example has received so many queries that they’ve launched a career center website for local biotech jobs in Virginia. Now while that’s all good and interesting, it doesn’t really address your question. What does is another project that the Virginia Biotechnology Association has established called VCATS.
VCATS is co-led by the Virginia Biotechnology Association, Virginia Manufacturers Association, and Training & Development Corporation. What these co-sponsors (and other states!) have realized is that there must be a program that solves the critical and growing skill shortage locally. With more than 100,000 retirements among manufacturing workers anticipated over the next ten years, including 45,000 technically skilled workers, Virginia is currently failing to qualify their replacements.
What VCATS does is provide an easily accessible solution to this problem. They are developing a three-tier certification system for work in biotechnology laboratories. This system will be recognized (at the very least) statewide, and may provide an innovative model for those regions not already considering programs like this. By setting basic standards, employers can hire with greater confidence, and more biotech businesses will know that Virginia is an attractive destination for them.
And speaking of employers… in Virginia alone, the local employers partnering and co-investing in VCATS include: Alcoa, Boehringer Ingelheim Chemicals, Merck, Micron Technologies, Novozymes Biologicals, Philip Morris, and Wyeth Pharmaceuticals. Other principal partners include the Maryland Biotechnology Association, Virginia Community College System, Virginia Career Education Foundation, Virginia Department of Business Assistance, and the Capital Area, Northern Virginia, and Richmond Workforce Investment Boards.
So I would encourage you to look up your local state or regional biotech organization (assuming you don’t live in Virginia) and ask if they too are starting a biotech certification program. It sounds like a perfect match for what you’re looking for.
at 1:53 PM
Scientist arrested for smuggling vials used in Ebola research into US
A Canadian scientist has been arrested for smuggling 22 vials stolen from Canada's National Microbiology Lab, used in Ebola and HIV research, into the United States, Canadian and US officials said Wednesday.
Konan Michel Yao, 42, "was taken into custody" while crossing the border from Manitoba province into the western US state of North Dakota on May 5, said a spokeswoman for the Public Health Agency of Canada, which operates the lab.
According to US prosecutor Lynn Jordheim, Yao was detained for carrying unidentified biological materials in vials wrapped in aluminium foil inside a glove and packaged in a plastic bag, along with electrical wires, in the trunk of his car.
Yao said in an affidavit he stole the vials, described as research vectors, from the Winnipeg lab on his last day of work there on January 21.
He told US border guards he was taking them to his new job with the National Institutes of Health at the Biodefense Research Laboratory in Bethesda, Maryland.
US authorities feared their contents could pose a terrorist threat. But tests later showed "they are not hazardous," said Jordheim.
"This turned out not to be a terrorism-related case," he said by telephone from North Dakota. "It appears to be exactly as he (Yao) said. However, he still faces possible charges for smuggling the vials into the United States."
Yao, meanwhile, remains in US custody after waiving his right to bail and preliminary hearings, as he awaits a possible grand jury indictment for smuggling, he said.
A Public Health Agency of Canada spokeswoman told AFP Yao "was working on vaccines for the Ebola virus and HIV, among other things."
"But he only had access to harmless and non-infectious materials, similar to what you'd find in a hospital or university lab. He did not have access to dangerous materials."
The Ivory Coast-born scientist is said to have studied at Laval University in Quebec and briefly worked at the University of Manitoba's plant sciences department.
at 10:12 AM
This is great news for Ed Leary's company, ContraVac. Several new products on the way.
Charlottesville company sends out its home male sterility tests
A Charlottesville biotech company has begun shipping out samples of its cutting-edge home tests for male sterility. ContraVac, located off Preston Avenue, is dispatching its SpermCheck Vasectomy test to urologists across the country.
The test, which is based on a protein discovered at the University of Virginia, aims to measure a man’s sperm count following a vasectomy.
According to the World Health Organization, a fertile male has a sperm count of 20 million sperm per milliliter. The SpermCheck Vasectomy tests if a vasectomy recipient has a sperm count of above or below 250,000 sperm per milliliter, essentially a trace level of sperm. ContraVac President and CEO Ed Leary said the home test can replace a follow-up appointment after a vasectomy operation. Often, he said, patients skip the follow-up appointment, during which they must provide a sperm sample.
“For the patient, it’s inconvenient and embarrassing,” he said.
A study that appeared recently in the British Journal of Medicine found that 35 percent of vasectomy patients do not return for their first sperm-level test following a vasectomy. More than 70 percent do not return for their second.
While the success rate of vasectomy operations is fairly high, one of every 238 vasectomies results in at least a partial failure, Leary said. The SpermCheck Vasectomy test ensures the procedure worked.
“There is an overall cost saving,” Leary said. “It saves the patient time and it saves the physician time.”
The test kit, which will soon be available at many urology practices and vasectomy clinics, carries a price tag of $39.99. Some 1.5 million men have vasectomies each year worldwide. In the United States, there are an estimated 500,000 such procedures each year. The Charlottesville company’s technology is based on inventions by the firm’s founder, John C. Herr, a UVa professor of cell biology and director of UVa’s Center for Research in Contraceptive and Reproductive Health.
ContraVac has another product, called Sperm-Check Fertility, which is targeted at couples trying to conceive. SpermCheck Fertility measures if a male’s sperm count is above or below 20 million sperm per milliliter, essentially showing if he is fertile or subfertile. ContraVac has filed for Food and Drug Administration approval of SpermCheck Fertility. The company expects the product will be approved by the end of July. SpermCheck Fertility will be sold at pharmacies across the country, Leary said, ideally alongside home pregnancy tests. The company is also working on a third product, a new contraceptive drug for men. The drug, called SpermCheck Contraception, is being tested in a multi-center National Institutes of Health-funded study.
“The SpermCheck family of products is intended for use by men on both sides of the fertility equation — those who don’t want to father children and those who do,” Herr said in a statement.
In an interview, Herr said it is exciting to see products finally come to market that are based on his scientific breakthroughs.
“It’s all coming together,” he said.
at 9:52 AM
AP story on Insmed's financial success since selling the FOB business to Merck...
Insmed swings to 1Q profit on Merck deal
RICHMOND, Va. (AP) - Insmed Inc. reported a first-quarter profit Wednesday, bolstered by Merck & Co. buying several of the biopharmaceutical company's drug candidates.
In February, Merck said it would pay $130 million to buy a slate of biotech drug candidates and a manufacturing facility from Insmed.
The company earned $117.8 million, or 96 cents per share, compared with a loss of $4.9 million, or 4 cents per share, during the period a year prior. Revenue remained flat at $2.4 million.
The swing to a profit came from the Merck deal, which included Insmed's biosimilar assets. Biosimilars are copies of biotech-based drugs. There is currently no approval process in place in the U.S., though Congress is debating several bills on the issue.
Insmed recorded a pretax gain of $127.8 million in the quarter from sale of assets.
The company, meanwhile, continues developing the muscular dystrophy treatment candidate Iplex.
Shares of Insmed fell 10 cents, or 7.3 percent, to $1.28 in afternoon trading. The stock has traded between 32 cents and $1.52 over the past 52 weeks.
at 9:48 AM
Wednesday, May 06, 2009
More than 80 bioscience industry guests attended a special "Biotech town hall" meeting organized by the Virginia Biotechnology Association (VaBIO) and the Biotechnology Industry Organization (BIO). Speakers included BIO CEO Jim Greenwood, Joe Trippi, Howard Dean's 2004 campaign manager and Ray Cypess, CEO of ATCC, the host venue for the event.
The event promoted social media avenues for advocates of the bioscience industry:
What Can Biotech Do for You? http://whatcanbiotechdoforyou.com/
I am Biotech: http://iambiotech.org/
VaBIO on Twitter: http://twitter.com/vabio
VaBIO on Facebook.
at 5:08 PM
Monday, May 04, 2009
More than eighty people turned out April 29th to support the Chesapeake Bioscience Education Foundation (C-BEF) at a special fundraiser at Indoor Biotechnologies in Charlottesville, Virginia. The event, “Biotech and Art After Hours,” was organized by the Virginia Biotechnology Association, and featured more than twenty works of art, Moroccan food, lab tours and networking with the crowd heavy with bioscience leaders from across the Piedmont region of the state.
“We couldn’t have been more pleased with the strong support we received for the Foundation,” said Mark A. Herzog, executive director of the Virginia Biotechnology Association (VaBIO). “The event was like nothing we had ever done before in terms of mixing works of art in a wet-lab environment. The patrons who attended really enjoyed the experience.”
Chesapeake Bioscience Education Foundation is a non-profit charitable organization that develops and promotes programs designed to encourage young students before they choose specific careers, to appreciate and participate in the challenging work of math and science so that they do not preclude subsequent career choices in the biosciences. Among other initiatives, C-BEF funds internships at eligible biotech companies through matching grants.
Photos of the event are available here:
In addition to VaBIO, the event was sponsored by the Charlottesville Business Innovation Council, the University of Virginia, Indoor Biotechnologies, Woods Rogers PLC, Birch Studio Graphics, Diffusion Pharmaceuticals, Afton Scientific, Garris and Company, PGxHealth and Klann Plastics.
at 1:13 PM